Featured Stories

Cost-effective Compound Testing with Single Mouse Trials


The Single Mouse Trial (SMT) format for in vivo patient-derived xenograft (PDX) studies addresses the need for more cost-effective compound testing in the larger, more diverse tumor populations that can be targeted using our vast portfolio of highly characterized models.

Within Walking Distance – A Cure for Cystic Fibrosis


On May 14, 2016, Charles River sponsored Great Strides®, a walk supporting the Cystic Fibrosis Foundation. The event brought more than 950 participants to the Cleveland Zoo and raised more than $270,000 to support the search for a cure.

That Was Fast: Health Surveillance Results in Record Time.


Continuous health surveillance is a critical task in resident animal colony management. Rapid, trusted results provide the information you need to make go/no-go decisions regarding contamination and to avoid the consequences of a biosecurity breach. Charles River has always provided timely, reliable data on every health monitoring sample we process. Our recent laboratory improvements will deliver even greater efficiency and value to our clients.

The Future of Rabbit Pyrogen Testing


During the last year, the move to replace the rabbit pyrogen test whenever possible has increased, especially in Europe. Companies should start to actively discuss this topic internally in order to determine the path forward.

FcγR-Binding Assays with HTRF Readout Now Available


Charles River now provides FcγR-binding assays with HTRF readout for FcγRI, -II, -III and FcγRn. These assays are used to measure the binding of therapeutic mAbs to Fcγ-receptors and are suitable for assessing biosimilarity.

Breaching the BBB


Intrathecal administration bypasses the blood-brain barrier (BBB) by accessing the spinal canal directly. Our scientists apply this technique to effectively deliver both small and large molecules.

How Do We Support the Fastest-Growing Area of Cancer Research?


Oncotest’s presence in Freiburg, Germany enables Charles River to extend development and availability of our robust portfolio of syngeneic models to clients in Europe, providing further support to immuno-oncology researchers across the globe.

Displaying results 41-50 (of 69)
 |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|